Q2 2026

Interim Report April – June
Xintela AB (Publ)

XSTEM achieved primary objective in difficult-to-heal leg ulcer study

Xintela raises a convertible loan of SEK 30 million

Osteoarthritis study results published in scientific journal

xintela

Summary of the interim report

The "Company" or "Xintela" refers to Xintela AB (publ), corporate registration number 556780-3480.

Significant events during the second quarter of 2026

- The company's net sales increased to SEK 1,317 thousand (872) during the second quarter, driven by work on the EQGen project. The pre-tax result improved to SEK -9,762 thousand (-12,119), due to higher net sales and lower costs.
- The safety results from Xintela's completed clinical study of XSTEM® in patients with difficult-to-heal venous leg ulcers have been analysed. XSTEM® was found to be safe and well tolerated, thereby achieving the primary objective of the study.
- The company's patent application for the use of Xintela's stem cell product XSTEM® for the treatment and regeneration of skin defects, including difficult-to-heal (chronic) wounds, has been granted in the USA.
- The company's patent application protecting the stem cell product XSTEM® for the treatment of Acute Respiratory Distress Syndrome (ARDS) and related diseases has been granted in Japan.
- The results from Xintela's preclinical study with EQSTEM® on horses with post-traumatic osteoarthritis, previously published in the scientific journal Cartilage, have been awarded best basic science paper 2025.
- Xintela announces that the company has entered into an agreement for a SEK 30 million convertible loan from its principal shareholder, Flerie Invest. The loan will be used to accelerate the development of XSTEM® and to repay a SEK 20 million loan from Fenja Capital.
- Xintela AB has entered into an agreement with Västra Hamnen Corporate Finance AB regarding services as Certified Adviser.

Significant events after the end of the period

- The results from Xintela's knee osteoarthritis study have been published in the scientific journal Cartilage. The publication supports that XSTEM® has a disease-modifying effect and is a very important validation of the study and Xintela's positive results.

Key figures

	The Group				Parent company			
(TSEK)	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025	Q2 2026	Q2 2025	Jan-Jun 2026	Jan-Jun 2025
Net sales	1,317	872	1,759	1,012	1,317	872	1,759	1,012
Loss before tax	-9,762	-12,119	-21,542	-22,780	-10,096	-10,711	-20,800	-19,286
Loss per share*, SEK	-0.01	-0.02	-0.03	-0.03	-	-	-	-

* Earnings per share: Profit for the period attributable to the parent company's shareholders divided by 861,266,841 shares, which is the average number of shares as of June 30, 2026. In the same period last year, the average number of shares was 667,111,179 shares.

Note to the reader
The "company" refers to Xintela AB (publ), corporate registration number 556780-3480. All figures are given in TSEK unless otherwise stated. Amounts in parentheses: Comparative period of the preceding year.

Trademarks
In addition to patents, the IP portfolio also currently includes seven trademarks - the company names XINTELA® and TARGINTA®, XINMARK® which is the name of Xintela's technology platform, and XSTEM® which is the name of Xintela's stem cell platform. EQSTEM® and CANISTEM® which are the company's brands for stem cell treatment for horses and dogs and XACT® which is the name of an analytical test for chondrocytes.

Focus on accelerating XSTEM's path to market

Following the positive clinical results with XSTEM, Xintela is now entering a new phase with a clear focus on business development, partnerships and accelerating XSTEM's path to market. The SEK 30 million convertible loan from our principal shareholder, Flerie Invest, gives us greater scope to implement this strategy and work on the company's long-term financing.

Strengthened financing and greater strategic flexibility
In June, we secured funding through a convertible loan of SEK 30 million from our principal shareholder, Flerie Invest. This funding has enabled us to repay ahead of schedule the SEK 20 million loan from Fenja Capital II A/S, which was raised in November 2025, whilst also giving us greater scope to pursue our priority activities and work on securing further funding. The continued support from our principal shareholder is significant and puts us in a better position to focus on the activities we believe have the greatest potential to create value.

Focus on accelerating the development of XSTEM for osteoarthritis
The positive results from our Phase I/IIa clinical trial with XSTEM for knee osteoarthritis form the basis of our ongoing strategy. The trial demonstrates that XSTEM significantly reduces pain and improves joint function, whilst also improving cartilage and bone tissue, which supports a disease-modifying effect.

We are continuously working to optimize the company's strategy. A primary goal for Xintela is to establish a partnership with an industrial partner for the continued clinical development and commercialisation of XSTEM. Such a partnership could provide both resources and commercial expertise, thereby accelerating the path to a broader market.

In parallel, we are evaluating the possibility of an earlier commercialisation of XSTEM in selected markets where regulatory conditions may permit its use based on existing clinical data. Such a strategy could generate early revenue and further clinical experience, as well as help to build the product's market position ahead of a broader international launch.

Primary objective achieved in our study on difficult-to-heal leg ulcers
In May, we reported the results from the completed clinical study on difficult-to-heal venous leg ulcers. The results showed that XSTEM was safe and well tolerated, thereby achieving the study's primary objective. Continued development of XSTEM in wound indications, we see primarily through a strategic partner.

» Translating our positive results into commercial opportunities

Organisational and operational changes ahead of the next phase
With our first two clinical trials now completed, Xintela is entering a new phase. We have therefore adapted our organisation and cost base to the activities that create the most value as we move into the next phase.

The team is now focusing on optimising and finalising the production process and analytical methods to prepare our stem cell product, XSTEM, for upcoming clinical trials and opportunities for early commercialisation. We are also working

intensively on business development, with a focus on partnerships and commercial agreements, as well as strategic efforts to optimise continued value creation within the company.

As part of these changes, Camilla Wennersten's role as Director of Clinical Development and Peter Ekolind's role as COO of the company are coming to an end. We would like to extend our warmest thanks to Camilla and Peter for their important contributions and great commitment in their roles and within the company's management.

Osteoarthritis results published in a scientific journal
The results from our knee osteoarthritis study have now been peer-reviewed and published in the scientific journal Cartilage. The publication describes the study's findings, which support a a disease-modifying effect of XSTEM, and discusses, amongst other things, how the results with XSTEM compare favourably with previously published results from osteoarthritis studies, whilst highlighting the benefits of Xintela's stem cell technology. This publication, which has been reviewed by independent experts in the field, provides a very important validation of the study and our positive results.

The way forward
Based on our positive preclinical and clinical results with XSTEM and a strong patent portfolio, we believe that Xintela is well-positioned to establish strategic and commercial collaborations in osteoarthritis and other relevant indications. In parallel with our ambition to land partnerships and long-term licensing deals, we are actively working to secure continued funding for Xintela to enable the company to achieve its strategic and operational objectives.

Following a period of intense focus on clinical studies, we are now entering a phase where our most important task is to translate our positive results into commercial opportunities and continued value creation. This will be our focus going forward.

Evy Lundgren-Åkerlund
Chief Executive Officer, Xintela AB (publ)

Stem cell-based therapies

The ability of stem cells to regenerate and repair damaged tissues and organs provides great hope for diseases that currently lack effective treatment.

Xintela is recognized for its unique stem cell product XSTEM, which has the potential to slow down and also cure a large number of diseases. XSTEM is in clinical development for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers.



Xintela is strongly positioned to develop and commercialize safe and effective stem cell treatments

Xintela has developed the competitive stem cell product XSTEM, which consists of integrin α10ß1-selected mesenchymal stem cells. Through the unique selection step in the production process, homogeneous stem cells of high and reproducible quality can be produced. XSTEM is manufactured in Xintela's own GMP facility and is patented both as a product and for therapeutic uses in all indications.



Mesenchymal stem cells have therapeutic properties

Xintela develops stem cell-based treatments from allogeneic (donated) mesenchymal stem cells isolated from adipose tissue from healthy adult donors. Stem cells from a donor can treat a large number of patients, which not only significantly reduces the cost of XSTEM compared to autologous (patient's own) stem cells but will also give physicians an off-the-shelf therapy. An important property of mesenchymal stem cells is their ability to transform into different cell types to regenerate and repair damaged tissues and organs. They also have the ability to stimulate damaged cells to self-repair. Another important property is that stem cells secrete various substances that can regulate the immune system and thus have anti-inflammatory effects.

Stem cell selection – a critical step in the production of XSTEM

Stem cell preparations produced from tissues are heterogeneous, i.e. they contain contaminating cells that are not stem cells. When developing a stem cell product, this is both a regulatory and functional problem.

Xintela solves the problem by selecting (purifying) stem cells using an antibody that binds to the company's stem cell marker, integrin α10ß1. In this way, homogeneous stem cell preparations of high quality can be produced that are reproducible between different donors.

Own GMP production of stem cells

Our stem cells are produced in bioreactors in the company's own GMP-approved facility and stored frozen until used in the treatment of patients. Through its in-house production facility Xintela has full control over the stem cell production which significantly reduces risks such as unexpected costs and delays. The company's strategy is to establish Xintela as a manufacturer of stem cell products developed in collaboration with partners and to also offer development and production of other advanced therapy products (ATMP).

Strong and sustained 24-month results with XSTEM in the osteoarthritis study

XSTEM shows disease-modifying potential on knee osteoarthritis
Xintela has completed a clinical study (Phase I/IIa) with the stem cell product XSTEM in Australia, in patients with moderate knee osteoarthritis (Kellgren-Lawrence grade II-III).

XSTEM shows excellent and sustained results 24 month after treatment. In the study, we have evaluated three different dose levels of XSTEM (4, 8 and 16 million stem cells) on a total of 24 patients (eight patients/dose level). Patients that received the two lowest dose levels of XSTEM completed the study 18 months after treatment and the results have previously been presented in an interim report. Patients at the highest dose level were evaluated after an additional six months, 24 months after treatment. The results continue to show that XSTEM is safe as well as a significant and clinically relevant reduction in knee pain, improved joint function and improved cartilage and bone structure, which confirms a long-lasting treatment effect and also shows that XSTEM has a disease-modifying potential.

Clinical study on difficult-to-heal venous leg ulcers shows safety
A clinical study with XSTEM has been conducted on difficult-to- heal venous leg ulcers. Six patients have been treated with XSTEM or placebo applied to the wound and evaluated over ten weeks and after four months. The study has reached the primary goal to demonstrate that the treatment is safe. A significant part of the study has been funded by a grant from Vinnova.

Market
Osteoarthritis
In 2024 the global osteoarthritis therapeutics market size was estimated at USD 9.13 billion, and the market is projected to reach USD 13.57 billion by 2030, growing at a compound annual growth rate of almost 7% from 2025 to 2030. This significant growth is driven by the rising prevalence of osteoarthritis, particularly among the aging population, and substantial R&D investments in new treatments.[1]

Venous leg ulcers
The global venous leg ulcer market size accounted for USD 2.25 billion in 2024 and is predicted to further grow from USD 2.57 billion in 2025 to approximately USD 8.47 billion by 2034, expanding at a compound annual growth rate of more than 14% from 2025 to 2034. The market is experiencing substantial growth driven by the rising prevalence of chronic venous insufficiency and an aging population, creating the need for effective wound care solutions. Advancements in compression therapies, bioactive therapies, and regenerative treatments are improving healing outcomes and reducing recurrence rates, thereby supporting market growth.[2]

Commercialization strategy for XSTEM
The company's overall strategy is to take the stem cell projects to Proof of Concept, by clinical Phase I/IIa studies, and then enter into partnerships and commercial agreements for continued clinical development and global commercialization. Xintela is very active in business development and has ongoing dialogue with potential partners and licensees within the pharmaceutical industry.



Osteoarthritis

Osteoarthritis is a joint disease characterized by degradation of the articular cartilage and impaired function of the cartilage cells. It is the most common chronic joint disease, especially in the knees, hips and hands, as well as the most common cause of disability in the elderly. The main symptoms are severe pain, inflammation, stiffness in the joint and reduced mobility. The disease affects about 25 percent of all individuals over the age of 60 and is increasing in extent due to an increasing elderly population. Drugs offered today are primarily pain-relieving and anti-inflammatory, which treat the symptoms but not the actual cause of the disease. [3, 4]

Difficult-to-heal leg ulcers

Difficult-to-heal leg ulcers in the elderly, including venous leg ulcers, are a major medical problem that results in pain and reduced quality of life for the patient, as well as large costs for healthcare systems. The incidence increases with age and is estimated to be about 4 percent among people over 65 years of age. Today's treatments for difficult-toheal leg ulcers include compression techniques and various surgical techniques, but there is a lack of effective drugs.[3, 4]

1 https://www.grandviewresearch.com/industry-analysis/osteoarthritis-therapeutics-market-report
2 https://www.precedenceresearch.com/venous-leg-ulcer-market
3 Global Data 2018
4 Markets and Markets 2020

A product platform for the treatment of several diseases

Xintela has conducted two clinical studies with the stem cell product XSTEM, in osteoarthritis and in difficult-to-heal leg ulcers, as well as a project for the treatment of ARDS in preclinical phase. In addition, Xintela has carried out preclinical studies with the stem cell product EQSTEM for the treatment of joint disease in horses.



Completion of the knee osteoarthritis study 24 months after XSTEM treatment
The clinical study (Phase I/IIa) has evaluated three different dose levels of XSTEM in a total of 24 patients (8 patients/dose level) with knee osteoarthritis. All patients have completed the 18-month follow-up and patients on the highest dose level has been evaluated for additional six months. The final analysis shows safety and positive efficacy data.

The difficult-to-heal leg ulcer study has been completed
The clinical study (phase I/IIa) has evaluated XSTEM for the treatment of difficult-to-heal venous leg ulcers in six patients. Safety and efficacy readings have been carried out weekly for ten weeks and four months after treatment. The results show that the primary objective of safety and tolerability has been achieved.

XSTEM shows therapeutic effect on Acute Respiratory Distress Syndrome (ARDS) in preclinical study
ARDS, acute respiratory distress syndrome, is a form of acute severe lung failure that can occur as a result of, for example, pneumonia, trauma or blood poisoning. The condition means that the lung function collapses and mortality is high. There is currently no effective treatment for ARDS. Xintela has successfully conducted preclinical studies for the treatment of ARDS with XSTEM in collaboration with Skane University Hospital and plans to carry out clinical development in collaboration with a partner.

EQSTEM shows disease modifying effect in preclinical horse models for osteoarthritis
Xintela has developed the stem cell product EQSTEM for the treatment of joint diseases in horses. Results from two preclinical studies in horses with post-traumatic osteoarthritis show disease modifying effect with reduces lameness and improved cartilage and bone structure. Xintela has signed a collaboration and license agreement with EQGen Biomedical for clinical development and commercialization of EQSTEM.

Antibody-based cancer therapies

Aggressive cancer is a challenge for clinical practice, diagnosis and treatment. There is a great need for new, targeted treatment strategies that can improve patients' survival and quality of life.

Targinta develops cancer-targeted antibodies for the treatment of aggressive cancers such as triple-negative breast cancer (TNBC), sarcoma and the brain tumor glioblastoma.



New cancer target and selective First-in-Class antibodies

Cancer target with unique properties
Xintela's subsidiary Targinta is developing new targeted and selective antibody-based drugs (First-in-Class) for the treatment of aggressive cancer. The company has been founded on its own discovery that Xintela's stem cell marker, integrin α10β1, is also expressed in aggressive cancers such as triple-negative breast cancer (TNBC) and the brain tumor glioblastoma.



The problem with most target molecules expressed in cancer is that the expression in normal tissues is relatively high. Integrin α10β1 is unique in this respect as it expression is very limited in normal tissue, which reduces the risk of off-target side effects. Integrin α10β1 is thus a very promising target molecule for the development of new and more selective cancer therapies.

Targinta's candidate drugs
Targinta is developing two types of antibodies, TARG9 and TARG10, for the treatment of aggressive cancer. TARG9 is a so-called Antibody-Drug Conjugate (ADC) and is armed with a powerful toxin that has a killing effect on cancer cells. TARG9 has shown significant inhibitory effect on the growth of glioblastoma tumors in preclinical models. TARG10 is a function-blocking antibody that slows down the growth and spread of cancer cells. TARG10 has in preclinical studies shown strong inhibitory effect on growth and metastasis of triple-negative breast cancer (TNBC).

Targinta positions itselfs in the ADC field
TARG9 was selected as the company's first candidate drug in the ADC area. This antibody has been developed with the latest ADC technology, which means a more powerful toxin that is well anchored to the antibodies as long as they circulate in the bloodstream, but which is released and activated when the antibody binds to and is taken up in cancer cells with integrin α10β1 on the surface. The interest in toxin-armed antibodies, ADCs, has increased significantly in recent years and the area is considered one of the hottest in oncology. A large number of commercial agreements have been made even at the early preclinical stage.

The market for triple-negative breast cancer and glioblastoma
The global market value for the treatment of triple-negative breast cancer is estimated to be approximately USD 2.1 billion by 2028 and for the treatment of glioblastoma to approximately USD 1.4 billion by 2026.[1, 2]

Commercialization strategy
Targinta's strategy is to enter into commercial agreements with the company's drug candidates during preclinical development to accelerate future clinical development and market appproval. Drug candidates against new target molecules on cancer cells, so-called First-in-Class products, are very attractive to drug development companies due to the great need for new and more effective cancer treatments.

Collaboration with Memorial Sloan Kettering Cancer Center
Targinta has entered into a collaboration with Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator in New York to clinically develop Targinta's integrin α10β1-targeted antibodies for the treatment of patients with aggressive sarcoma.

Triple-negative breast cancer

Triple-negative breast cancer, i.e. breast cancer that responds neither to hormone therapy nor to targeted treatment with HER2 antibodies, constitutes 10-15 percent of all breast cancer diagnoses and corresponds to approximately 300,000 new cases per year globally. It spreads and recurs to a greater extent and has a worse prognosis compared to other forms of breast cancer. The five-year survival rate for metastatic triple-negative breast cancer is about 12 percent.[3, 4]

Glioblastoma

Glioblastoma (glioblastoma multiforme) is the most common and aggressive brain tumor in adults. Glioblastoma is characterized by the tumor cells rapidly spreading into the adjacent normal brain tissue, which contributes to the difficulty of removing the entire tumor without damaging the surrounding tissue. Glioblastoma cells are often resistant to both radiation and cytostatics and, as a result, the prognosis for patients is very poor. Approximately 55,000 people are estimated to be diagnosed with the disease annually in the 8 largest markets (USA, France, Germany, Italy, Spain, UK, Japan and China).[5, 6, 7]

1 American Cancer Society https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-nega-tive.html
2 GlobalData: Glioblastoma Multiforme (GBM) Opportunity Analysis and Forecast to 2027
3 https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negative.html#:~:tex-t=Triple%2Dnegative%20breast%20cancer%20(TNBC,of%20the%20protein%20called%20HER2
4 American Cancer Society https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negati-ve.html
5 WebMD: https://www.webmd.com/cancer/brain-cancer/what-is-glioblastoma#1
6 American Association of Neurological Surgeons: https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme
7 Global Data: Epidemiology and Market size Database

Financial Statements



Income statement in brief

Earnings
Operating loss for the second quarter amounted to TSEK -9,683 (-11,526) for the Group.

The costs for research and development account for the largest part of the group´s costs and for the period April to June amounted to TSEK -7,634 (-9,367).

Market and sales costs for the quarter amounted to TSEK -1,074 (-989) for the Group.

Administrative expenses for the period amounted to TSEK -2,291 (-2,042) for the Group.

Loss before tax for the period amounted to TSEK -9,762 (-12,119) for the Group.

Under the heading "Tax on profit for the period", tax is booked as income. This refers to the estimated amount of the tax refund paid by the Australian Taxation Office to Xindu, for parts of the costs incurred by the subsidiary Xindu for the clinical studies in 2025. No tax is booked in 2026 as the clinical study has been completed.

	Quarter 2		Half year		Full year
(TSEK)	2026-04-01 2026-06-30	2025-04-01 2025-06-30	2026-01-01 2026-06-30	2025-01-01 2025-06-30	2025-01-01 2025-12-31
Operating income					
Net sales	1,317	872	1,759	1,012	2,282
Cost of goods sold	0	0	0	0	0
Gross profit	**1,317**	**872**	**1,759**	**1,012**	**2,282**
Operating expenses					
Research and development costs	-7,634	-9,367	-16,077	-16,666	-35,953
Selling costs	-1,074	-989	-2,255	-1,904	-3,701
Administrative expenses	-2,291	-2,042	-4,376	-4,062	-9,312
Other operating income	0	0	60	0	0
Other operating expenses	0	0	0	0	0
Operating loss	**-9,683**	**-11,526**	**-20,889**	**-21,620**	**-46,684**
Profit/loss from financial items					
Financial income	0	0	0	5	13
Financial expenses	-79	-594	-654	-1,166	-3,487
Loss before tax	**-9,762**	**-12,119**	**-21,542**	**-22,780**	**-50,158**
Tax on loss for the period	0	160	0	394	1,594
Loss for the period	**-9,762**	**-11,959**	**-21,542**	**-22,386**	**-48,564**
Loss per share, SEK	**-0,01**	**-0,02**	-0,03	-0,03	**-0,07**

Balance sheet in brief

Financial position
On June 30, 2026 the group's cash and cash equivalents amounted to TSEK 30,724 (10,532). Total assets amounted to TSEK 35,098 (18,236).

(TSEK)	2026-06-30	2025-12-31
ASSETS		
Fixed assets		
Intangible assets	0	0
Tangible assets	159	320
Total fixed assets	**159**	**320**
Current assets		
Inventory	334	705
Accounts receivable	0	0
Tax receivable	0	0
Other receivables	3,068	3,328
Prepaid expenses	812	1,465
Cash and cash equivalents	30,724	23,208
Total current assets	**34,939**	**28,705**
TOTAL ASSETS	**35,098**	**29,025**

(TSEK)	2026-06-30	2025-12-31
EQUITY AND LIABILITIES		
Equity, the group		
Share capital	25,838	25,838
Other contributed capital	419,723	419,723
Reserve	353	765
Balanced result incl. Profit for the year	-473,141	-451,599
Total equity	**-27,227**	**-5,273**
Current liabilities		
Accounts payable	6,474	5,149
Tax liability	193	161
Convertible loan	30,000	0
Other liabilities	21,894	22,417
Accrued expenses and deferred income	3,764	6,572
Total current liabilities	**62,325**	**34,299**
TOTAL EQUITY AND LIABILITIES	**35,098**	**29,025**

Cash flow statement in brief

Cash flow and investments
The group's cash flow for the period April to June 2026 was TSEK 20,860 (4,005). Investments for the period amounted to TSEK 0 (-70) for the Group.

	Quarter 2		Half year		Full year
(TSEK)	2026-04-01 2026-06-30	2025-04-01 2025-06-30	2026-01-01 2026-06-30	2025-01-01 2025-06-30	2025-01-01 2025-12-31
Operating activities					
Operating loss	-9,683	-11,526	-20,889	-21,620	-46,684
Depreciation/amortisation	100	151	231	303	606
Taxes	0	0	0	0	2,049
Financial income	0	0	0	5	13
Financial expenses	-79	-594	-654	-1,166	-3,487
Cash flow from operating activities before changes in working capital	**-9,662**	**-11,968**	**-21,312**	**-22,477**	**-47,503**
Changes in working capital					
Increase/decrease in receivables	337	-1,227	1,214	178	1,834
Increase/decrease in current liabilities	185	7,140	-1,974	6,031	4,051
Changes in working capital	**522**	**5,913**	**-760**	**6,209**	**5,885**
Cash flow from operating activities	**-9,140**	**-6,055**	**-22,072**	**-16,268**	**-41,618**
Investing activities					
Increase/decrease of tangible assets	0	-70	0	-70	0
Increase/decrease of intangible assets	0	0	0	0	0
Increase/decrease of financial assets	0	0	0	0	0
Cash flow from investing activities	**0**	**-70**	**0**	**-70**	**0**
Financing activities					
New share issue, TO3	0	10,130	0	10,130	10,110
New share issue, December	0	0	0	0	38,919
Bridge loan, Flerie	0	0	0	0	-20,500
Bridge loan, Fenja	0	0	0	0	20,000
Convertible loan	30,000	0	30,000	0	0
Cash flow from financing activities	**30,000**	**10,130**	**30,000**	**10,130**	**48,529**
Change in cash and cash equivalents	20,860	4,005	7,928	-6,208	6,911
Cash and cash equivalents at the beginning of the period	9,783	6,398	23,208	16,680	16,680
Conversion difference	81	129	-412	60	-383
Cash and cash equivalents at the end of the period	**30,724**	**10,532**	**30,724**	**10,532**	**23,208**

Change in equity in brief

(TSEK)	Share capital	Other contributed capital	Reserves	Loss for the period	Total
Opening balance, January 1, 2025	**19,974**	**376,557**	**555**	**-403,036**	**-5,950**
Conversion difference	0	0	210	0	210
New share issue, TO3 June	1,013	9,117	0	0	10,130
New share issue, TO3 costs	0	-20	0	0	-20
New share issue, TO3 December	4,851	37,191	0	0	42,042
New share issue, TO3 costs	0	-3,123	0	0	-3,123
Loss for the period	0	0	0	-48,564	-48,564
Equity, December 31, 2025	**25,838**	**419,723**	**765**	**-451,599**	**-5,273**
Opening balance, January 1, 2026	**25,838**	**419,723**	**765**	**-451,599**	**-5,273**
Conversion difference	0	0	-412	0	-412
Loss for the period	0	0	0	-21,542	-21,542
Equity, June 30, 2026	**25,838**	**419,723**	**353**	**-473,141**	**-27,227**

Income statement in brief

Income
The parent company reports a net turnover of TSEK 1,317 (872) for the second quarter of the year.

Earnings
Loss for the second quarter amounted to TSEK -10,359 (-10,433) for the Parent Company .

The costs for research and development account for the largest part of the Company's costs and amounted to TSEK -8,430 (-8,414) for the period April to June.

Market and sales costs for the quarter amounted to TSEK -1,074 (-989) for the Parent Company.

Administrative expenses for the period amounted to TSEK -2,171 (-1,902) for the Parent Company.

The financial income amounts to 328 (311) KSEK and refers to internal interest between Xintela and Xindu for the period April to June 2026.

Loss before tax for the period April to June amounted to TSEK -10,096 (-10,711) for the Parent Company.

	Quarter 2		Half year		Full year
(TSEK)	2026-04-01 2026-06-30	2025-04-01 2025-06-30	2026-01-01 2026-06-30	2025-01-01 2025-06-30	2025-01-01 2025-12-31
Operating income					
Net sales	1,317	872	1,759	1,012	2,282
Cost of goods sold	0	0	0	0	0
Gross profit	**1,317**	**872**	**1,759**	**1,012**	**2,282**
Operating expenses					
Research and development costs	-8,430	-8,414	-16,199	-14,100	-28,228
Selling costs	-1,074	-989	-2,255	-1,904	-3,701
Administrative expenses	-2,171	-1,902	-4,159	-3,811	-8,962
Other operating income	0	0	60	0	0
Other operating expenses	0	0	0	0	0
Operating loss	**-10,359**	**-10,433**	**-20,794**	**-18,803**	**-38,608**
Profit/loss from financial items					
Financial income	328	311	634	669	1,220
Financial expenses	-66	-589	-640	-1,152	-3,467
Loss before tax	**-10,096**	**-10,711**	**-20,800**	**-19,286**	**-40,856**
Appropriations	0	0	0	0	-2,669
Tax on loss for the year	0	0	0	0	0
Loss for the period	**-10,096**	**-10,711**	**-20,800**	**-19,286**	**-43,524**

Balance sheet in brief

Financial position
On June 30, 2026 the parent company's equity/assets ratio was 23 per cent (40) and equity amounted to TSEK 18,611 (24,749).
The Parent company's cash and cash equivalents amounted to TSEK 30,636 (10,346). Total assets amounted to TSEK 80,367 (61,205).

(TSEK)	2026-06-30	2025-12-31
ASSETS		
Fixed assets		
Intangible assets	0	0
Tangible assets	105	201
Receivables from subsidiaries	33,329	31,161
Participations in subsidiaries	13,926	13,926
Total fixed assets	**47,360**	**45,288**
Current assets		
Inventory	334	705
Accounts receivable	0	0
Tax receivable	0	0
Other receivables	1,225	1,618
Prepaid expenses	812	1,004
Cash and cash equivalents	30,636	22,806
Total current assets	**33,007**	**26,133**
TOTAL ASSETS	**80,367**	**71,421**

(TSEK)	2026-06-30	2025-12-31
EQUITY AND LIABILITIES		
Equity, parent company		
Share capital	25,838	25,838
Share premium reserve	419,723	419,723
Retained earnings	-406,150	-362,626
Loss for the period	-20,800	-43,524
Total equity	**18,611**	**39,411**
Current liabilities		
Accounts payable	6,245	4,950
Tax liability	193	161
Convertible loan	30,000	0
Other liabilities	21,581	22,182
Accrued expenses and deferred income	3,737	4,718
Total current liabilities	**61,756**	**32,011**
TOTAL EQUITY AND LIABILITIES	**80,367**	**71,421**

Cash flow statement in brief

Cash flow and investments
The parent company's cash flow for the period April to June was 21,093 (4,356) TSEK. Receivables from subsidiaries increased for the period by -1,163 (-1,487) TSEK.

	Quarter 2		Half year		Full year
(TSEK)	2026-04-01 2026-06-30	2025-04-01 2025-06-30	2026-01-01 2026-06-30	2025-01-01 2025-06-30	2025-01-01 2025-12-31
Operating activities					
Operating loss	-10,359	-10,433	-20,794	-18,803	-38,608
Depreciation/amortisation	33	73	96	147	294
Financial income	328	311	634	669	1,220
Financial expenses	-66	-589	-640	-1,152	-3,467
Cash flow from operating activities before changes in working capital	**-10,063**	**-10,638**	**-20,704**	**-19,139**	**-40,562**
Changes in working capital					
Increase/decrease in receivables	192	-1,207	957	-10	617
Increase/decrease in current liabilities	2,127	7,558	-255	7,350	3,405
Changes in working capital	**2,319**	**6,351**	**702**	**7,340**	**4,021**
Cash flow from operating activities	**-7,744**	**-4,287**	**-20,002**	**-11,799**	**-36,540**
Investing activities					
Increase/decrease of tangible assets	0	0	0	0	0
Increase/decrease of receivables from subsidiaries	-1,163	-1,487	-2,168	-4,319	-5,517
Cash flow from investing activities	**-1,163**	**-1,487**	**-2,168**	**-4,319**	**-5,517**
Financing activities					
New share issue, TO3	0	10,130	0	0	10,110
New share issue, December	0	0	0	10,130	38,919
Bridge loan, Flerie	0	0	0	0	-20,500
Bridge loan, Fenja	0	0	0	0	20,000
Convertible loan	30,000	0	30,000	0	0
Cash flow from financing activities	**30,000**	**10,130**	**30,000**	**10,130**	**48,529**
Change in cash and cash equivalents	21,093	4,356	7,830	-5,988	6,471
Cash and cash equivalents at the beginning of the period	9,543	5,989	22,806	16,334	16,334
Cash and cash equivalents at the end of the period	**30,636**	**10,346**	**30,636**	**10,346**	**22,806**

Change in equity in brief

(TSEK)	Share capital	Other contributed capital	Reserves	Loss for the period	Total
Opening balance, January 1, 2025	**19,974**	**376,557**	**-329,031**	**-33,595**	**33,905**
Reversal of prior year's accruals	0	0	-33,595	33,595	0
New share issue, TO3 June	1,013	9,117	0	0	10,130
New share issue, TO3 costs	0	-20	0	0	-20
New share issue, TO3 December	4,851	37,191	0	0	42,042
New share issue, TO3 costs	0	-3,123	0	0	-3,123
Loss for the period	0	0	0	-43,524	-43,524
Equity, December 31, 2025	**25,838**	**419,723**	**-362,626**	**-43,524**	**39,411**
Opening balance, January 1, 2026	**25,838**	**419,723**	**-362,626**	**-43,524**	**39,411**
Reversal of prior year's results	0	0	-43,524	43,524	0
Loss for the period	0	0	0	-20 800	-20 800
Equity, June 30, 2026	**25,838**	**419,723**	**-406,150**	**-20,800**	**18,611**

Declaration by the Board of Directors and the CEO

The Board of Directors and the Chief Executive Officer certify that the interim report provides a true and fair view of the company's business, financial position, performance and describes material risks and uncertainties, to which the company is exposed.

The interim report has not been reviewed by the company's auditors.

Lund, August 28, 2026

Thomas Eldered
Chairman

Jonas Ekblom
Board member

Tobias Hägglöv
Board member

Lars Hedbys
Board member

Hans-Joachim Simons
Board member

Evy Lundgren-Åkerlund
CEO


Thomas Eldered


Jonas Ekblom


Tobias Hägglöv


Lars Hedbys


Hans-Joachim Simons


Evy Lundgren-Åkerlund

Other information

The share
Xintela AB (publ) was listed on Nasdaq First North Growth Market in Stockholm on 22 March 2016 under the ticker symbol "XINT." First North Growth Market is an alternative marketplace, operated by an exchange within the NASDAQ OMX Group. Companies on First North Growth Market are not subject to the same rules as companies on the regulated main market. They are subject to a less regulated framework, adapted for small growth companies. A company listed on First North Growth Market may therefore entail a higher investment risk than a company listed on the main market. All companies listed on First North Growth Market have a Certified Adviser to oversee their compliance with the rules. The exchange assesses applications for admission to trading. Xintela's Certified Adviser on Nasdaq First North Growth Market is Västra Hamnen Corporate Finance AB.

On 30 june 2026, the number of shares was 861,266,841. The Company has only one class of shares. Each share carries identical rights to the Company's assets and earnings, and one vote at General Meetings.

Financial statements in accordance with K3
This report has been prepared in accordance with BFNAR 2012:1 Annual Report and Consolidated Financial Statements (Q3) and the accounting principles are unchanged compared with those applied in the Annual Report for 2025. For complete accounting principles, see the Annual Report 2025.

Group accounts
The consolidated accounts include the companies in which the parent company directly or indirectly holds more than half of the votes for all shares, or otherwise has a controlling influence according to ÅRL 1:4. The company's earnings are included in the group's earnings from and including the acquisition date until it is divested. The financial statements of foreign subsidiaries have been recalculated according to the current rate method. All items in the balance sheet have been converted to the balance sheet exchange rate. All items in the income statement have been converted to average exchange rates during the financial year. Differences that arise are reported directly in equity.

Review by auditors
This interim report has not been reviewed by the Company's auditor.

Financial calendar
Interim report Q3 2026: 27 November 2026
Interim report Q4 2026: 26 February 2027

Risks and uncertainties
Limited resources
Xintela is a small company with limited resources in terms of management, administration, and capital. The implementation of any major strategies requires optimization of the Company's resource appropriation. There is a risk that the Company's resources could be insufficient, and lead to financial and operational problems. The company's ability to continue its operations depends on the ongoing work with the company's financing being successful. Focused work is underway to secure the company's future financing and the Board's assessment is that we will successfully secure future financing needs.

Dependence on key individuals and employees
Xintela's success is based on the knowledge, experience, and creativity of a few specific individuals. The Company's future is dependent on being able to recruit qualified employees. The Company works hard to reduce this dependency by maintaining proper documentation of procedures and working methods.

Earning capacity and capital requirements
Drug development is both expensive and time-consuming. It may take longer than expected before the Company can generate a positive cash flow. To cover these costs, Xintela may need to raise new capital. There is no guarantee that such capital can be obtained on terms that are favorable to shareholders. Failure to generate sufficient profits may impact the Company's market value.

Sales risk
There is no certainty that the products developed by the Company will gain the market acceptance reflected in this interim report. The quantity of products sold may be lower, and the period required for market establishment may be longer, than the Company currently has reason to believe.

	Quarter 2		Full year
	Jan–Jun 2026	Jan–Jun 2025	Jan–Dec 2025
No. of shares before full dilution	861,266,841	699,564,681	861,266,841
No. of shares after full dilution	897,152,959	699,564,681	897,152,959
Loss per share before full dilution	-0.01	-0.02	-0.07
Average no. of shares before full dilution	861,266,841	667,111,179	689,735,560
Average no. of shares after full dilution	897,152,959	667,111,179	725,621,678








Xintela – for life in motion

Xintela develops stem cell-based treatments focusing on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancer. The focus is on diseases that cause great suffering and lack effective medical treatment options.

Xintela's stem cell product XSTEM is in clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers. The goal with the studies is to show that XSTEM treatment is safe, but also investigate XSTEM's ability to repair damaged cartilage and improve the joint function and to effectively heal leg ulcers, thereby reduce pain and suffering and improve quality of life for many patients.

Within oncology, tumor-targeting and armed antibodies are developed for aggressive cancers such as triple negative breast cancer and the brain tumor glioblastoma. Results from preclinical models have shown that the antibodies have an inhibitory effect on both the growth and metastasis of cancer cells. The drug candidates TARG9 and TARG10 are in preclinical development.

Contact

Xintela AB
Medicon Village
223 81 Lund, Sverige
+46 46,275 65 00
info@xintela.se

Investor Relations

Evy Lundgren-Åkerlund, CEO
evy@xintela.se

xintela